Integrating Comparative Evidence to Optimize Psoriasis Treatment Decisions

In the final episode, "Integrating Comparative Evidence to Optimize Psoriasis Treatment Decisions," the panelists explore how the full body of available evidence, including comparative analyses, long term extension studies, real world data, and clinical experience, can be integrated into practical treatment decision making for plaque psoriasis.

The panel opens by outlining the distinct role each type of evidence plays in clinical practice. Comparative studies including MAICs, network meta-analyses, and head to head trials are valued for helping clinicians identify which therapy is most likely to work best for a given patient when all else is equal. Long term extension studies are primarily used to provide patients with reassurance around safety, offering years of accumulated clinical trial safety data with no new emerging signals. Real world data is highlighted as particularly valuable for informing drug persistence and helping clinicians select a therapy that patients are likely to stay on long term, reducing the burden of frequent switching for both the patient and the clinical team. The panel also acknowledges the role of anecdotal clinical experience, noting that when personal observations align with what is seen across clinical trial and real world data, it creates a compelling and well supported basis for treatment recommendations.

The discussion then turns to how community practice dermatologists can apply comparative evidence in their daily practice, with the panel emphasizing the importance of understanding what MAICs are and how to interpret them in the absence of head to head trial data. The panel acknowledges that real world evidence takes time to generate, making other data sources particularly important when evaluating newer agents.

The episode concludes with a summary of the strengths of the IL-23 inhibitor class, including superior efficacy, infrequent dosing, and a strong safety profile, and reinforces that each piece of evidence, from phase three trials to real world analyses, contributes to a complete picture that enables truly holistic and patient centered treatment decisions.

Thank you for watching this Peer Exchange series on psoriasis. Please subscribe to our newsletter for information on upcoming video series.